GLP-1 Drug Surge Reshapes the Diabetic Food Market

GLP-1 Drugs Put $73B in Global Food Brand Value at Risk, Reshaping Diabetic Food Sector 

NEW YORK, United States September 22, 2026, a new report from brand valuation consultancy Brand Finance has found that the world's 100 most valuable food brands face a combined $73 billion risk as surging adoption of GLP-1 weight-loss and diabetes medications fundamentally alters consumer eating habits, with direct implications for the diabetic food market as food manufacturers accelerate their pivot toward health-conscious, lower-calorie product portfolios. 

The Brand Finance analysis, which assessed the top 100 food brands globally collectively valued at $278 billion determined that approximately one quarter of that total is structurally at risk from shifting consumption patterns driven by GLP-1 medications. The findings arrive as the global diabetic food market is projected to reach USD 19.38 billion by 2030, growing at a compound annual growth rate of 6.2%, according to Next Move Strategy Consulting. 

The scale of GLP-1 adoption is accelerating rapidly. According to a Gallup update published in September 2026, approximately 11% of U.S. adults currently take appetite-suppressing GLP-1 medications for weight loss nearly quadrupling from 3% in 2024. With an estimated 137 million Americans eligible for these drugs, the downstream effects on food purchasing behavior are already measurable: a Cornell University study found that grocery spending fell 6% in households containing at least one GLP-1 user. 

The Brand Finance report identified PepsiCo's Lay's as the single most exposed food brand globally, with $6.8 billion of its $15.1 billion brand value at risk. PepsiCo's five major snack brands collectively carry $14.1 billion in exposure. Doritos, Hershey's, Cheetos, Kellogg's, and Reese's were also identified as highly vulnerable, with seven of the ten most exposed food brands worldwide headquartered in the United States. 

Confectionery, chocolate, and savory snacks together account for 53% of the total brand value at risk, despite representing only 30% of overall brand value in the analysis underscoring the disproportionate exposure of indulgent food categories to the GLP-1 trend. 

Key Highlights: 

• $73 billion in combined brand value across the world's top 100 food brands is at structural risk from rising GLP-1 drug adoption, per Brand Finance's latest report. 

• GLP-1 users consume an estimated 700 fewer calories per day and are most likely to reduce intake of processed foods, sugar-sweetened beverages, and refined grains categories that overlap significantly with traditional snack portfolios. 

• Major food companies are responding with targeted product innovation: Nestlé launched its Vital Pursuit brand for GLP-1 users in 2024, Danone introduced an Oikos yogurt drink for muscle retention, and Conagra Brands added a "GLP-1 friendly" label to select Healthy Choice frozen meals. 

• Beverage brands including Gatorade, Aquafina, Minute Maid, and Monster are identified as beneficiaries of GLP-1-driven consumption shifts, as consumers increasingly seek hydration, functionality, and health-oriented products. 

Analyst Insight: 

According to analysts at Next Move Strategy Consulting, the GLP-1-driven restructuring of consumer food preferences represents a structural tailwind for the diabetic food segment. As millions of patients managing diabetes and metabolic conditions shift away from high-calorie, high-sugar processed foods, demand for low-glycemic, nutrient-dense, and portion-controlled alternatives is expected to intensify directly benefiting manufacturers operating in the diabetic-friendly food space. 

NMSC analysts further note that the convergence of rising diabetes prevalence, expanding GLP-1 drug eligibility, and heightened consumer health awareness is compressing the timeline for food companies to reposition their portfolios. Brands that proactively invest in diabetic-friendly product lines, clean-label formulations, and functional nutrition stand to capture a disproportionate share of the market's projected growth through 2030. 

Industry Outlook: 

The Brand Finance findings signal a pivotal inflection point for the global food industry, with the diabetic food segment positioned to absorb a meaningful share of the demand being redirected away from conventional snack and confectionery categories. As GLP-1 drug adoption continues to broaden particularly in the United States, where more than half of all adults are now eligible food manufacturers face mounting pressure to align their innovation pipelines with the dietary requirements of a growing population managing diabetes, prediabetes, and metabolic conditions. 

The trend is already prompting strategic acquisitions, such as Ferrero's purchase of better-for-you brand Purely Elizabeth, and accelerating private-label protein and fiber initiatives across major grocery retailers. For the diabetic food market, the sustained rise in diabetes-related health searches and GLP-1 prescriptions is less a disruption than a demand signal one that is expected to sustain the sector's growth trajectory through the end of the decade.

Source: Grocery Dive 

For More Information: Download FREE Sample on Diabetic Food Market Report

Prepared By: Sanyukta Deb